Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MICHAEL E JONES

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1083611636
CMS profile
94620
Location
CRESTVIEW HILLS, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$257.93

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $257.93 9

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Scientific Affairs, LLC $103.75 1
ABBVIE INC. $94.98 5
Nestle HealthCare Nutrition Inc. $35.64 2
Gilead Sciences, Inc. $23.56 1

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MICHAEL E JONES

NPI 1083611636 · CMS profile ID 94620

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CRESTVIEW HILLS, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1083611636?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1083611636?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1083611636?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MICHAEL E JONES, NPI 1083611636, CMS profile ID 94620, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1083611636?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $257.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $11.9408/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892965205 CMS
ABBVIE INC. $25.4006/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892965201 CMS
ABBVIE INC. $22.1604/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892965197 CMS
Nestle HealthCare Nutrition Inc. $17.5204/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902781573 CMS
Janssen Scientific Affairs, LLC $103.7503/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887215475 CMS
ABBVIE INC. $18.1303/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892965193 CMS
ABBVIE INC. $17.3501/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892965189 CMS
Nestle HealthCare Nutrition Inc. $18.1201/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902781571 CMS
Gilead Sciences, Inc. $23.5601/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929524781 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $217.85 9
PY2020 $129.84 7
PY2021 $337.52 11
PY2022 $257.93 9
PY2023 $258.68 17
PY2024 $310.01 9
PY2025 $392.84 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $304,950.60 133
PY2024 Principal investigator $457,323.22 237
PY2023 Principal investigator $533,333.42 238
PY2022 Principal investigator $150,301.11 166
PY2021 Principal investigator $55,731.60 19
PY2020 Principal investigator $143,151.70 114
PY2019 Principal investigator $258,588.69 68

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,814.00 12/17/2021 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 2b3 Randomized Double blind Placebo controlled Parallel group Multi Center Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 787797485
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $795.00 12/10/2021 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 816784247
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $636.00 12/10/2021 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 816784257
Principal investigator 1 ABBVIE INC. $2,819.80 11/17/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792482991
Principal investigator 1 ABBVIE INC. $8,568.40 10/14/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792479289
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $635.40 09/29/2021 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816762233
Principal investigator 1 ABBVIE INC. $753.20 09/09/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792474927
Principal investigator 1 ABBVIE INC. $1,214.00 07/29/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792470045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,875.30 07/27/2021 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816746659
Principal investigator 1 ABBVIE INC. $1,302.80 06/30/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792465087
Principal investigator 1 ABBVIE INC. $8,555.20 06/08/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792462465
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,209.40 05/25/2021 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816728173
Principal investigator 1 ABBVIE INC. $1,330.40 05/05/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792453611
Principal investigator 1 ABBVIE INC. $1,130.00 05/05/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792453615
Principal investigator 1 IRONWOOD PHARMACEUTICALS, INC $1,000.00 05/03/2021 Non-covered Recipient Entity
TRI-STATE GASTROENTROLOGY ASSOCIATES
C3718-302 No dispute reported 06/30/2026 831599073
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,489.00 04/27/2021 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIATES PSC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE-DAILY ORAL ADMINISTRATION OF A PERIPHERALLY ACTING DOPAMINE RECEPTOR D2/D3 ANTAGONIST, TAK-906 FOR THE TREATMENT OF ADULT SUBJECTS WITH SYMPTOMATIC IDIOPATHIC OR DIABETIC GASTROPARESIS No dispute reported 06/30/2026 816717349
Principal investigator 1 Janssen Research & Development, LLC $109.20 03/29/2021 Non-covered Recipient Entity
TRI-STATE GASTROENTEROLOGY ASSOCIAT ES
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787797503
Principal investigator 1 ABBVIE INC. $2,428.00 03/02/2021 Non-covered Recipient Entity
TRISTATE GASTROENTEROLOGY ASSOCIATES
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792429115
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,066.50 01/06/2021 Non-covered Recipient Entity
TRI STATE GASTROENTEROLOGY ASSOCIATES
A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE No dispute reported 06/30/2026 816678295